Humacyte Bolsters Board with Commercialization Vets Ahead of Key Launches
Event summary
- Humacyte added Scott Coward and Paul Kuznik to its board on September 28, 2026.
- Coward brings public company governance and legal expertise from Exact Sciences and K&L Gates.
- Kuznik offers vascular healthcare commercialization experience from Bolton Medical and Terumo.
- Coward joins the Audit Committee; Kuznik joins the Commercial Committee.
- Appointments coincide with Symvess® launch expansion and planned ATEV dialysis access launch.
The big picture
These appointments signal Humacyte's focus on commercial-scale execution as it transitions from clinical-stage to commercial-stage biotech. The additions of Coward and Kuznik reflect strategic priorities in governance and vascular market penetration, critical as the company prepares for multiple product launches. The moves come amid growing competition in regenerative medicine and increasing demand for innovative vascular solutions.
What we're watching
- Commercialization Execution
- Whether Kuznik's vascular expertise can accelerate ATEV's dialysis access launch timeline.
- Governance Dynamics
- How Coward's public company experience influences Humacyte's strategic decision-making.
- Regulatory Pathways
- The pace at which Humacyte advances additional ATEV indications through FDA approval.
Related topics
